Table 3.

Biomarker evaluations in novel targeted agents in triple-negative breast cancer.

Drug	Target	Potential biomarker	Phase of study	Ongoing evaluation
Olaparib	Poly ADP ribose polymerase	BRCA mutation	Phase II	Phase I and II in combination
Iniparib	Unknown	BRCA mutation	Phase II	None documented
APR-246 [Lehmann et al. 2012]	Mutant p53	P53 mutation	Phase I	None documented
ENMD-2076 [Diamond et al. 2013]	Aurora kinase VEGFR2/KDR	P53 mRNA and protein expression	Preclinical	Phase II [ClinicalTrials.gov identifier: NCT01639248]
Everolimus [Yunokawa et al. 2012]	mTOR	EGFR CK5/6	Preclinical	No studies specific to TNBC
Dasatinib [Finn et al. 2007]	Src and other kinases BCR-ABL	Moesin Caveloin YAP-1	Preclinical	Phase II did not report biomarkers [Finn et al. 2011]
Trametinib [Jing et al. 2012]	MEK 1/2	DUSP6	Preclinical	Phase I kinome study [ClinicalTrials.gov identifier: NCT01467310]